Clinical trial
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With…
NCT00099268 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00099268 |
|---|---|
| Title | Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy |
| Official title | A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy |
| Acronym | STRIDE-PD |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | Orion Corporation, Orion Pharma Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa |
| Enrollment | 747 |
| Start date | Sep 1, 2004 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Dec 10, 2004 |
| Last update posted | Apr 23, 2012 |
| Countries | Austria, Belgium, Canada, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, Turkey (Türkiye) and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: